Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 9/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5515215 | 0.91 | TNF (0.41) | TNFKDM4EDPP4ALDH1A1HPGD | |
| SCHEMBL5512764 | 0.90 | TNF (0.39) | TNFKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL5511478 | 0.90 | TNF (0.39) | TNFKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL5516130 | 0.86 | KDM4E (0.42) | KDM4EDPP4CSNK1DALDH1A1HPGD | |
| SCHEMBL5512207 | 0.86 | MYC (0.42) | KDM4EDPP4CSNK1DALDH1A1HPGD | |
| SCHEMBL5512916 | 0.86 | KDM4E (0.44) | KDM4EDPP4CSNK1DALDH1A1HPGD | |
| SCHEMBL5515946 | 0.85 | LMNA (0.44) | TNFALDH1A1HTTLMNAMAPT | |
| SCHEMBL5524774 | 0.85 | KDM4E (0.43) | KDM4EDPP4CSNK1DALDH1A1HPGD | |
| SCHEMBL5511556 | 0.84 | KDM4E (0.40) | KDM4EDPP4CSNK1DALDH1A1HPGD | |
| SCHEMBL5512857 | 0.83 | KDM4E (0.38) | KDM4EDPP4ALDH1A1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238812-B2 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEJI SEIKA KAISHA, LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20060074074-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| US-7022860-B2 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1026167-B1 | TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND ANTIALLERGIC AGENTS | MEIJI SEIKA KAISHA (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-20020137739-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2002-09-26 | — | — | US | disclosed |
| US-6372735-B1 | ANTIHISTAMINES | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| EP-1026167-A1 | TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND ANTIALLERGIC | MEIJI SEIKA KAISHA LTD. (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074074-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | HRH4, CYP2D6, CYP2B6 | TNF 4043/4885KDM4E 752/4885DPP4 719/4885 |
| US-20020137739-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | HRH4, CYP3A4, TPH1 | TNF 4581/4885KDM4E 547/4885DPP4 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.